- Record: found
- Abstract: found
- Article: not found
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
David A Eberhard
1 ,
Bruce E Johnson ,
Lukas C Amler ,
Audrey D Goddard ,
Sherry L Heldens ,
Roy S Herbst ,
William L Ince ,
Pasi A Jänne ,
Thomas Januario ,
David H Johnson ,
Pam Klein ,
Vincent A Miller ,
Michael A Ostland ,
David A Ramies ,
Dragan Sebisanovic ,
Jeremy A Stinson ,
Yu R Zhang ,
Somasekar Seshagiri ,
Kenneth J Hillan
Sep 01 2005
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Epidermal growth factor receptor (EGFR) mutations have been associated with tumor response to treatment with single-agent EGFR inhibitors in patients with relapsed non-small-cell lung cancer (NSCLC). The implications of EGFR mutations in patients treated with EGFR inhibitors plus first-line chemotherapy are unknown. KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described.